Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Christina Cox

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Cancer Letters|October 21, 2021
Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worldsMaria Christina Cox, Guido Bocci
Cancer Letters|April 18, 2024
Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedulesMarta Banchi, Maria Christina Cox, Guido Bocci
Cancer Immunology, Immunotherapy : CII|April 24, 2020
Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphomaMaria Christina Cox, Caterina Lapenta, Stefano M Santini
Journal of Leukocyte Biology|July 3, 2015
Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactionsSimone Battella, Maria Christina Cox, Angela Santoni, et al.
Expert Review of Hematology|November 19, 2010
Prognostic tools in follicular lymphomasStefano Luminari, Maria Christina Cox, Antonella Montanini, et al.
Cancers|September 28, 2023
Serum Paraprotein Is Associated with Adverse Prognostic Factors and Outcome, across Different Subtypes of Mature B-Cell Malignancies-A Systematic ReviewMaria Christina Cox, Fabiana Esposito, Massimiliano Postorino, et al.
Diagnostics (Basel, Switzerland)|May 30, 2020
Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma Not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the LiteratureAlessandro Mangogna, Maria Christina Cox, Luigi Ruco, et al.
Chemotherapy|August 7, 2023
Complete Remission of a Diffuse Large B-Cell Lymphoma in a Young Patient, with Severe Tuberous Sclerosis, Treated with Metronomic Chemotherapy and Ibrutinib: A Case ReportMarta Banchi, Tiziana Lanzolla, Arianna Di Napoli, et al.
Anticancer Research|December 25, 2009
Radioimmunotherapy of heavily pre-treated, non-Hodgkin's lymphoma patients: efficacy and safety in a routine settingFrancesco Cicone, Rossella Baldini, Maria Christina Cox, et al.
Scientific Reports|April 2, 2025
Synergistic activity of tafasitamab and metronomic chemotherapy on diffuse large B-cell lymphoma through inhibition of the AKT/mTOR signaling pathwayMarta Banchi, Maria Christina Cox, Paola Orlandi, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Cancer Letters|October 21, 2021
Metronomic chemotherapy regimens and targeted therapies in non-Hodgkin lymphoma: The best of two worldsMaria Christina Cox, Guido Bocci
Cancer Letters|April 18, 2024
Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedulesMarta Banchi, Maria Christina Cox, Guido Bocci
Cancer Immunology, Immunotherapy : CII|April 24, 2020
Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphomaMaria Christina Cox, Caterina Lapenta, Stefano M Santini
Journal of Leukocyte Biology|July 3, 2015
Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactionsSimone Battella, Maria Christina Cox, Angela Santoni, et al.
Expert Review of Hematology|November 19, 2010
Prognostic tools in follicular lymphomasStefano Luminari, Maria Christina Cox, Antonella Montanini, et al.
Cancers|September 28, 2023
Serum Paraprotein Is Associated with Adverse Prognostic Factors and Outcome, across Different Subtypes of Mature B-Cell Malignancies-A Systematic ReviewMaria Christina Cox, Fabiana Esposito, Massimiliano Postorino, et al.
Diagnostics (Basel, Switzerland)|May 30, 2020
Rituximab Plus Chemotherapy Provides No Clinical Benefit in a Peripheral T-Cell Lymphoma Not Otherwise Specified with Aberrant Expression of CD20 and CD79a: A Case Report and Review of the LiteratureAlessandro Mangogna, Maria Christina Cox, Luigi Ruco, et al.
Chemotherapy|August 7, 2023
Complete Remission of a Diffuse Large B-Cell Lymphoma in a Young Patient, with Severe Tuberous Sclerosis, Treated with Metronomic Chemotherapy and Ibrutinib: A Case ReportMarta Banchi, Tiziana Lanzolla, Arianna Di Napoli, et al.
Anticancer Research|December 25, 2009
Radioimmunotherapy of heavily pre-treated, non-Hodgkin's lymphoma patients: efficacy and safety in a routine settingFrancesco Cicone, Rossella Baldini, Maria Christina Cox, et al.
Scientific Reports|April 2, 2025
Synergistic activity of tafasitamab and metronomic chemotherapy on diffuse large B-cell lymphoma through inhibition of the AKT/mTOR signaling pathwayMarta Banchi, Maria Christina Cox, Paola Orlandi, et al.
Pageof 6